OPC1
Acute Spinal Cord Injury
Phase 1/2aActive
Key Facts
About lineage-cell-therapeutics
Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.
View full company profile